术前新辅助化疗治疗Ⅰb-Ⅱb宫颈癌近期疗效分析

Curative Effect of Preoperative Neoadjuvant Chemotherapy in the Treatment of Stage Ⅰb-Ⅱb Cervical Cancer

目的探讨术前新辅助化疗治疗Ⅰb-Ⅱb期宫颈癌的近期疗效。方法选取我院术前行新辅助化疗的57例Ⅰb-Ⅱb期宫颈癌患者。其中术前采用静脉新辅助化疗者25例,术前介入化疗者(术前动脉介入栓塞化疗+手术)32例。分析比较两组患者术后病理不良因素及高危因素发现率、术后并发症发生率,术中出血及近期疗效。结果两组患者病理不良因素和高危因素发现率无显著差异(P>0.05);两组患者术后并发症发生率及术后近期临床疗效无显著差异(P>0.05);介入化疗组术中出血量显著高于静脉化疗组(P<0.05)。结论术前静脉与介入新辅助化疗Ⅰb-Ⅱb期宫颈癌临床疗效确切,但介入化疗组患者的术中出血较多。

Objective To evaluate the clinical efficacy of preoperative neoadjuvant chemotherapy in treating stageⅠb-IIb cervical cancer. Methods 57 cases of patients with stageⅠb-IIb cervical cancer received preoperative neoadjuvant chemotherapy were selected. 25 cases were given the intravenous neoadjuvant chemotherapy, 32 cases received the preoperative interventional chemotherapy （preoperative arterial interventional embolism chemotherapy plus surgery）. The discovery rate of postoperative pathologic adverse factors and risk factors, the incidence of postoperative complications, the hemorrhage during operation and short-term effects were compared. Results The discovery rate of pathologic adverse factors and risk factors of the two groups had no significant difference （P 〉0.05）; the incidence of postoperative complications and short-term effects of the two groups had no significant difference （P 〉0.05）; the hemorrhage of the interventional chemotherapy group was significantly higher than that of the intravenous neoadjuvant chemotherapy group （P 〈0.05）. Conclusions The interventional and intravenous neoadjuvant chemotherapy are effective in the treatment of stageⅠb-IIb cervical cancer, but the patients in the interventional chemotherapy group are bleeding more during operation.